ArticleClinical and vaccine immunology : CVI2009
Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection.
Article in Clinical and vaccine immunology : CVI, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Impact of Chlamydia trachomatis in the reproductive setting: British Fertility Society Guidelines for practice.Human fertility (Cambridge, England) · 2010Guideline
- Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo.Scientific reports · 2021Trial
- Comparison of three serological assays to measure antibody response to Chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease.International journal of STD & AIDS · 2018Trial
- Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area.Scientific reports · 2018Trial
- Serum IgG1 and IgG3 Antibodies to Chlamydia trachomatis Pgp3 and Hsp60 in Men of Subfertile Couples.The Journal of infectious diseases · 2026Article
- Monitoring of Chlamydia trachomatis infection and antibodies in low-prevalence districts of Amhara, Ethiopia: Insights from a hyper-endemic trachoma region.PLoS neglected tropical diseases · 2026Article
- Serum IgG1 and IgG3 Antibody Responses to Chlamydia trachomatis Pgp3 and Hsp60 in Tubal Factor Infertility.The Journal of infectious diseases · 2025Article
- Maternal-fetal transfer and longitudinal trends of antibodies to Chlamydia trachomatis and Mycoplasma genitalium in early childhood.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Comparison of Chlamydia trachomatis Seroprevalence and Risk Factors for Infection Among Women by Gender/Sex of Sex Partner, United States, 2013-2016.Sexually transmitted diseases · 2025Article
- Risk factors associated with IgG seropersistence toEpidemiology and infection · 2025Article
- Challenges in Chlamydial Serology: Insights from a Belgian and a Dutch Population Cohort.Microorganisms · 2024Article
- Antibody responses toFrontiers in cellular and infection microbiology · 2024Article
- The serodiagnositic value ofFrontiers in public health · 2024Article
- Association between serumFrontiers in public health · 2023Article
- What Can Serology Tell Us About the Burden of Infertility in Women Caused by Chlamydia?The Journal of infectious diseases · 2021Review
- Seroprevalence of Chlamydia trachomatis Among Female Adults in the United States: The National Health and Nutrition Examination Surveys.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Seroepidemiology ofFrontiers in microbiology · 2021Article
- Association of Past Chlamydia trachomatis Infection With Miscarriage.JAMA network open · 2020Article
- Article
- Antibody Testing in Estimating Past Exposure to CMicroorganisms · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
Understanding of the burden of Chlamydia trachomatis infection and its clinical sequelae is hampered by the absence of accurate, well-characterized tests using serological methods to determine past exposure to infection. An "in-house" immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) based on the C. trachomatis-specific antigen Pgp3 was produced and evaluated against three commercial ELISAs derived from the major outer membrane protein: the Medac pELISA plus, the Savyon SeroCT-IgG ELISA, and the Ani Labsystems IgG enzyme immunoassay. Sensitivities and specificities were determined using sera from both male and female patients (n = 356) for whom C. trachomatis had been detected in the lower genital tract at least 1 month prior to the testing of the sample and from 722 Chlamydia-negative children aged 2 to 13 years. The Pgp3 ELISA was significantly more sensitive (57.9% [95% confidence interval {95% CI}, 52.7 to 62.9%]) than the Ani Labsystems (49.2% [95% CI, 44.0 to 54.3%]; P = 0.003), SeroCT (47.2% [95% CI, 42.1 to 52.4%]; P < 0.0005), and Medac (44.4% [95% CI, 39.3 to 49.6%]; P < 0.0005) ELISAs. The Pgp3, Ani Labsystems, and SeroCT assays, but not the Medac assay, had significantly higher sensitivity for female specimens than for male specimens (73.8 versus 44.2%, 59.8 versus 40.5%, 55.5 versus 40%, and 45.7 versus 43.7%, respectively). For female patients, the Pgp3 assay was 14.0% (95% CI, 5.5 to 22.5%) more sensitive than the next most sensitive ELISA, the Ani Labsystems assay (P = 0.001). There was no significant difference in specificity between the Pgp3 (97.6% [95% CI, 96.2 to 98.6%]), Ani Labsystems (99% [95% CI, 97.7 to 99.6%]), SeroCT (97.2% [95% CI, 95.7 to 98.2%]), and Medac (96% [95% CI, 94.3 to 97.2%]) ELISAs. None of the ELISAs showed evidence of cross-reactivity with antibodies to Chlamydia pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.